Lamotrigine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Lamotrigine is a anticonvulsant drug that is FDA approved for the {{{indicationType}}} of Bipolar I disorder Lennox-Gastaut syndrome; Adjunct Partial seizure, Adjunct or monotherapy Tonic-clonic seizure, Primary generalized; Adjunct. Common adverse reactions include rash abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia, ataxia, coordination problem, dizziness, headache, insomnia, somnolence, tremor, vertigo, blurred vision, diplopia , anxiety, depression, dysmenorrhea, rhinitis, pain.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Bipolar I disorder
- Lennon-Gastaut syndrome; Adjunct
- Partial seizure, Adjunct or monotherapy
- Tonic-clonic seizure, Primary generalized; Adjunct
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information about Off-Label Guideline-Supported Use of Lamotrigine in adult patients.
Non–Guideline-Supported Use
- Bipolar disorder, depressed phase
- Convulsions in the newborn, Intractable
- Depression, Treatment-resistant; Adjunct
- Epilepsy, Refractory
- Migraine
- Obesity
- Obsessive-compulsive disorder, Resistant, as adjunct therapy to serotonin reuptake inhibitors
- Trigeminal neuralgia
There is limited information about Off-Label Non–Guideline-Supported Use of Lamotrigine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Lamotrigine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information about Off-Label Guideline-Supported Use of Lamotrigine in pediatric patients.
Non–Guideline-Supported Use
There is limited information about Off-Label Non–Guideline-Supported Use of Lamotrigine in pediatric patients.
Contraindications
There is limited information regarding Lamotrigine Contraindications in the drug label.
Warnings
There is limited information regarding Lamotrigine Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Lamotrigine Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Lamotrigine Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Lamotrigine Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Lamotrigine in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Lamotrigine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Lamotrigine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Lamotrigine in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Lamotrigine in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Lamotrigine in geriatric settings.
Gender
There is no FDA guidance on the use of Lamotrigine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Lamotrigine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Lamotrigine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Lamotrigine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Lamotrigine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Lamotrigine in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Lamotrigine Administration in the drug label.
Monitoring
There is limited information regarding Lamotrigine Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Lamotrigine and IV administrations.
Overdosage
There is limited information regarding Lamotrigine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
| |
| |
Lamotrigine
| |
| Systematic (IUPAC) name | |
| 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine | |
| Identifiers | |
| CAS number | |
| ATC code | N03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
| Mol. mass | 256.091 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | 98% |
| Protein binding | 55% |
| Metabolism | Hepatic (mostly UGT1A4-mediated) |
| Half life | 29 hours |
| Excretion | Urine (65%), faeces (2%) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. | |
| Legal status |
Prescription Only (S4)(AU) ?(CA) POM(UK) [[Prescription drug|Template:Unicode-only]](US) |
| Routes | Oral |
Mechanism of Action
There is limited information regarding Lamotrigine Mechanism of Action in the drug label.
Structure
There is limited information regarding Lamotrigine Structure in the drug label.
Pharmacodynamics
There is limited information regarding Lamotrigine Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Lamotrigine Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Lamotrigine Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Lamotrigine Clinical Studies in the drug label.
How Supplied
There is limited information regarding Lamotrigine How Supplied in the drug label.
Storage
There is limited information regarding Lamotrigine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Lamotrigine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Lamotrigine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Lamotrigine Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Lamotrigine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Lamotrigine Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Lamotrigine Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.